Research and Markets: Global Acute Lymphoblastic Lymphoma Pipeline Report 2015 - 4 Companies & 5 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/tjzjcl/acute) has announced the addition of the "Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Acute Lymphoblastic Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphoblastic Lymphoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • EpiZyme, Inc.
  • Juno Therapeutics Inc.
  • Novartis AG
  • Zymeworks Inc.

Drug Profiles

  • Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies
  • EPZ-5676
  • JCAR-014
  • midostaurin
  • ZW-38

For more information visit http://www.researchandmarkets.com/research/tjzjcl/acute

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology